Unique ID issued by UMIN | UMIN000047487 |
---|---|
Receipt number | R000054131 |
Scientific Title | The effects of peptide on mental health in adults: A randomized, double-blind, placebo-controlled study |
Date of disclosure of the study information | 2022/04/15 |
Last modified on | 2022/10/18 13:27:05 |
The effects of peptide on mental health in adults: A randomized, double-blind, placebo-controlled study
The effects of peptide on mental health in adults: A randomized, double-blind, placebo-controlled study
The effects of peptide on mental health in adults: A randomized, double-blind, placebo-controlled study
The effects of peptide on mental health in adults: A randomized, double-blind, placebo-controlled study
Japan |
None
Not applicable | Adult |
Others
NO
To evaluate the efficacy of peptide on mental health.
Safety,Efficacy
Japanese version of POMS2
1) VAS (fatigue, stress, sleep)
2) STAI
3) Stress markers in saliva
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
Ingestion of the test food for 4 weeks.
Ingestion of the placebo food for 4 weeks.
20 | years-old | <= |
65 | years-old | > |
Male and Female
1) 20-64 years old.
2) Subjects with mental health complaints.
1) Subjects who use supplements, functional foods, or drugs associated with mental health.
2) Subjects with a history of and/or current mental illness or suspicion of mental illness.
3) Subjects who are undergoing medical treatment or have a previous medical history of serious diseases.
4) Subjects who have excessive alcoholic drinks (more than 60 g/day of alcohol).
5) Subjects who have severe drug allergy or severe food allergy, and/or a previous medical history of such allergies.
6) Subjects who participated in other clinical studies within 1 month before giving informed consent to participate in this study, or are planning to participate in other studies during this study.
7) Subjects who are pregnant or lactating, or who are expected to be pregnant during the study.
8) Subjects who are judged as ineligible to participate in this study by the principal investigator based on their background, physical findings, and so on.
140
1st name | Masahiko |
Middle name | |
Last name | Nakamura |
Matsumoto City Hospital
Hospital Director
390-1401
4417-180 Hata, Matsumoto, Nagano, Japan
0263-92-3027
hospi@city.matsumoto.lg.jp
1st name | Katsuya |
Middle name | |
Last name | Furuhata |
Matsumoto Health Lab
None
390-0811
M wing 1F, 1-18-1, Chuo, Matsumoto, Nagano, Japan
0263-39-1139
info@m-health-lab.jp
Matsumoto City Hospital
Morinaga Milk Industry Co., Ltd.
Profit organization
Research Ethics Committee of Matsumoto City Hospital
4417-180 Hata, Matsumoto, Nagano, Japan
0263-92-3027
hospi@city.matsumoto.lg.jp
NO
2022 | Year | 04 | Month | 15 | Day |
Unpublished
Completed
2022 | Year | 01 | Month | 25 | Day |
2022 | Year | 01 | Month | 25 | Day |
2022 | Year | 04 | Month | 18 | Day |
2022 | Year | 07 | Month | 24 | Day |
2022 | Year | 04 | Month | 14 | Day |
2022 | Year | 10 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054131
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |